Aarti Pharmalabs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹610 Cr +45.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
AP

Aarti Pharmalabs Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Aarti Pharmalabs Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹564Cr
+11.5% YoY
+4.8% QoQ
Net profit
₹88Cr
+35.4% YoY
+18.9% QoQ
Margin
26%
+3 pp YoY
+2 pp QoQ
Price₹817
Market cap₹6.2K Cr
P/E35.0

The short version

The company targets around 15% revenue growth in FY'26. FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth.

From Aarti Pharmalabs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets around 15% revenue growth in FY'26.
  • CDMO business is expected to grow 30%-40% in FY'26, contributing approximately 15%-16% of total revenue.
  • Xanthine business aims for Rs. 1,000 crore to Rs. 1,250 crore in revenue with 80%-90% capacity utilization by FY'29.
  • API & Intermediates segment growth driven by regulated markets and new product launches, particularly anti-cancer and anti-diabetic drugs.
  • New products and launches expected over next 2-3 years will contribute to growth, strengthening market share.
  • Atali plant commercialization expected by FY'26 end, with phased operationalization supporting capacity expansion.

2 more points from Aarti Pharmalabs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY'25 CAPEX: Around Rs. 400 crores spent.
  • FY'26 CAPEX guidance: Rs. 400-450 crores planned.
  • Major CAPEX break-up for Rs. 800-850 crores cumulative over FY'25 and FY'26:
  • Atali Greenfield project: Rs. 400-425 crores.
  • Xanthine capacity expansion: Rs. 150 crores.
  • Solar plant: Rs. 85 crores.
  • Other smaller projects and R&D: approx. Rs. 40 crores annually.
  • Atali project mechanical completion expected by end of current quarter; operational ramp-up phased through FY'26.
  • Xanthine capacity expansion (to 9,000 MT) commissioned phased in H2 FY'26, fully operational by Q1 FY'27.
  • Solar plant payback expected in about 3.5 to 4 years, with cost savings materializing in FY'26.

2 more points from Aarti Pharmalabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Aarti Pharmalabs is currently working with 21 customers in the CDMO/CMO segment.
  • The number of active projects has increased to 61 (from 56 last quarter).
  • Out of these, 33 projects are at the commercial stage, and 27 are under various development stages at the customer's end.
  • Approximately 70-75% of the commercialized projects contributed to revenue in FY'25.

2 more points from Aarti Pharmalabs Ltd's call on order book

Create a free account to keep reading this call

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aarti Pharmalabs Ltd Q4 FY25 results — key figures

Aarti Pharmalabs Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue564506+11.5%538+4.8%
Operating profit (EBITDA)146118+23.7%129+13.2%
Operating margin26%23%+3 pp24%+2 pp
Profit before tax11596+19.8%101+13.9%
Net profit (PAT)8865+35.4%74+18.9%
EPS (₹)9.757.20+35.4%8.16+19.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q4 FY25 results?

The company targets around 15% revenue growth in FY'26. FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth.

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

FY'25 CAPEX: Around Rs. 400 crores spent.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.